Details for New Drug Application (NDA): 021226
✉ Email this page to a colleague
The generic ingredient in KALETRA is lopinavir; ritonavir. There are thirteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the lopinavir; ritonavir profile page.
Summary for 021226
Tradename: | KALETRA |
Applicant: | Abbvie |
Ingredient: | lopinavir; ritonavir |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 133.3MG;33.3MG | ||||
Approval Date: | Sep 15, 2000 | TE: | RLD: | No |
Expired US Patents for NDA 021226
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | KALETRA | lopinavir; ritonavir | CAPSULE;ORAL | 021226-001 | Sep 15, 2000 | ⤷ Subscribe | ⤷ Subscribe |
Abbvie | KALETRA | lopinavir; ritonavir | CAPSULE;ORAL | 021226-001 | Sep 15, 2000 | ⤷ Subscribe | ⤷ Subscribe |
Abbvie | KALETRA | lopinavir; ritonavir | CAPSULE;ORAL | 021226-001 | Sep 15, 2000 | ⤷ Subscribe | ⤷ Subscribe |
Abbvie | KALETRA | lopinavir; ritonavir | CAPSULE;ORAL | 021226-001 | Sep 15, 2000 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription